Sequenom has had its share of legal problems in recent years, from scandals involving insider trading to a former executive releasing misleading information on a new prenatal Down syndrome test.
But that was then and this is now, Neumann said, because the biotech company has moved on and is focused on the future.
"The most satisfaction I get out of the job is working on things that are productive and help the business grow," Neuman...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In